QureBio Raises ￥10M in Pre-B Round of Financing

According to PEdaily.cn, Shanghai-based Qure Biotechnology Co., Ltd. ("QureBio") announced today the completion of its Pre-A round of tens of millions, with participation from Xinhenglida Capital and other investors. This round of financing funds will mainly be used to promote the pre-clinical development of Q-1802 and Q-1801 projects.

Previously, QureBio has raised three rounds of financing: in April this year, it obtained ￥10 million Series A+ round of financing from Shenzhen Capital Group； in August 2019, it completed ￥10 million Series A financing jointly invested by Jundu Investment and Wosheng Capital; In May 2017, the angel round financing of nearly 10 million yuan was completed.

Founded in July 2017, QureBio is a research and development company focusing on the innovation of macromolecular drugs. The company aims to treat cancers, autoimmune diseases and metabolic diseases (such as diabetes, hyperlipidemia, etc.) and other difficult diseases, and actively develop biological therapy drugs.

QureBio has a number of independent platforms, covering the humanization platform of hybridoma antibody, phage display, single-domain antibody development, and antibody engineering. The company successfully completed several multiple transmembrane-spanning antigen projects by using its antibody humanization platform to solve the problem of immune tolerance. The synthesis library of human single-domain antibody and human antibody of the phage platform can be used to screen bispecific antibodies. 

Relying on these platforms, QureBio is developing new biologics and has nearly 10 pipelines under development, most of which are aimed at the challenging treatment of solid tumors.

Q-1802 can target two tumor antigens of solid tumors, such as gastric cancer, and three batches of pilot production have been completed so far. Q-1801 project is a bi-specific antibody drug intervening in the tumor microenvironment signaling pathway, which is expected to complete the clinical application in 2021.

Headquartered in Shenzhen, Xinhenglida Capital is a private equity company focusing on the early-stage investment in new energy/new materials, medical and health services, consumption, mobile Internet/Internet of Things (IoT) and other fields.